Since the 1980s, China has actively promoted the development of biotechnology industries. Favorable policies, national special funds, and inflows of private capital have greatly facilitated the progress of China's biotechnology industry. Basic research and applied transformation research achievements have advanced side by side, and remarkable results have been made in several mainstream fields of frontier biotechnology. In recent years, with the reform of China's drug review and approval system and the integration of biotechnology R&D with international standards, outstanding Chinese biotechnology enterprises have gradually gained international recognition and embarked on an internationalization strategy of going global.
The internationalization strategy of Chinese biotech enterprises is an inevitable path for future development. The internationalization strategy can not only help enterprises open up global markets and maximize the value of products, technologies, and platforms, but also enable Chinese companies to learn from advanced management experience and technology in competition and cooperation with outstanding international biotech enterprises and multinational corporations. Currently, a series of excellent Chinese biotech enterprises have begun to go global, gradually exploring various types of cross-border cooperation models in independent research and development and commercial licensing, to promote their own internationalization strategy.
Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') was established in 1961, with its global headquarters located in New York, USA. It connects to Wall Street financial markets, reaches over 1,000+ financial industry companies, and has offices in major regions around the world. Over its 63-year development history, it has provided consulting services to more than 10,000 international companies in various fields, becoming a globally renowned growth consulting firm with extensive influence and brand power in multiple industry sectors and financial markets.
Frost & Sullivan's professional research reports and industry insights have attracted attention from media worldwide. It has established deep collaborations with top global communication agencies (such as The Associated Press and United Press Syndicate), mainstream financial media (such as Yahoo Finance), top North American financial media and websites (including Business Insider, Dow Jones MarketWatch, Benzinga, Wall Street Insider, etc.), as well as top regional media around the globe. Leveraging Frost & Sullivan's professional industry analysis, global distribution network, and global industrial resource network, it effectively assists Chinese biotech companies in their internationalization strategy.
Greg Caressi
Partner, Global Client Leader & Senior Vice President, Frost & Sullivan
"Frost & Sullivan is a global growth consulting firm with a 63-year history. We are delighted to leverage our influence and global resource network to assist more Chinese biotech companies in realizing their internationalization strategies, to foster the integrated development of the global healthcare sector."
Dr. Wang Xin
Global Partner and Chairman of Frost & Sullivan Greater China Region
"Since entering the Chinese market in 1998, Frost & Sullivan has always been proactive in helping Chinese enterprises achieve capital operation goals such as financing and listing, with a global perspective. It has helped numerous Chinese brands go global. In recent years, the R&D capabilities and technological innovation of domestic biotech companies have gradually gained international recognition, further encouraging them to actively explore new models of international development, open up broad overseas markets, and seek new incremental growth. In the future, we will continue to leverage our expertise and influence to help Chinese biotech companies seize certainty in the global wave and realize their international strategic ambitions."
Jiangsu Frost & Sullivan Biotechnology Co., Ltd. (referred to as Frost & Sullivan Biotechnology) is an industry-leading platform enterprise in synthetic biology driven by innovation, deeply involved in the field of collagen. Frost & Sullivan, in collaboration with Frost & Sullivan Biotechnology, has released the report globally.Recombinant Type XVII Collagen WhitepaperCombining Frost & Sullivan's professional database and expert team, the report conducts an in-depth analysis of the current situation and development trends of the Chinese collagen market. It provides a detailed analysis of the Chinese XVII-type collagen market, its applications, and development prospects. The report is also published in collaboration with several globally renowned media outlets to raise global awareness of the collagen industry and showcase the technical and platform advantages of outstanding enterprise, Chuangjian Medical, thereby promoting the internationalization of the Chuangjian Medical brand.
Recombinant Type XVII Collagen WhitepaperGlobal release
The white paper was published on the Frost & Sullivan global website and included in the global database.
Since its establishment in 1961 and development to date, Frost & Sullivan has become a global growth consulting firm covering various industries and regions. The Frost & Sullivan database contains research reports and in-depth insights from nearly 50 offices around the world, integrating professional knowledge to provide a global perspective. It tracks over 1,000 emerging technology fields and analyzes industry development and application prospects.
The Frost & Sullivan Global Database covers various sub-industry directions, with the life sciences sector being one of the most important. The research reports included in the Frost & Sullivan Global Database enjoy a high level of recognition in the global life sciences industry and serve as a window for biopharmaceutical companies, medical device companies, biotech firms, government agencies, financial institutions, investment companies, university research centers, and other organizations to understand industry growth opportunities. With the help of the Frost & Sullivan Global Database, the global biotechnology industry can gain close insights into the development of China's biotechnology industry, recognize the technical platforms and product R&D capabilities of Chinese biotech enterprises, as well as their latest progress. It is also an important platform for Chinese biotech enterprises to promote their internationalization.
Published by 10+ global core media
Published by several globally influential media, including Associated Press, one of the world's largest communication agencies; Yahoo Finance, a mainstream financial media; Business Insider, a top North American financial media and website; Dow Jones Market Watch, Benzinga, Street Insider, and others.
Included in over 700 global media outlets
Based on Frost & Sullivan's global brand influence and professional analysis capabilities, the published content has been included in multiple media outlets. This helps enterprises further enhance their brand awareness globally, deepen their understanding of enterprise technology and products, and facilitate the internationalization of their brands.
……
Scan the QR code to get the report now
About Chuangjian Medical
Jiangsu Chuangjian Medical Technology Co., Ltd. (Chuangjian Medical) was established in 2015. It is a platform enterprise that drives the entire synthetic biology industry with innovation. It owns a biosynthesis platform and a medical device transformation platform, focusing on the research, development, production, and sales of new biomaterials, innovative proteins, nucleic acid drugs, and food products. It holds 5 authorized core sequence patents for recombinant collagen in the field of recombinant collagen. In July 2022, Chuangjian Medical successfully completed nearly 200 million yuan in Series A financing, led by the Capital Joy Fund exclusively funded by Zishengtang China, with Huafang Capital, Dinhui Bafu, and Huali Medicine participating as follow-on investors. In September 2023, it completed over 200 million yuan in Series B financing, jointly led by L Catterton (Chinese name: Lu Weikaiteng) and CITIC Lyon Capital, with Chuangfang Investment and Mingfeng Capital participating as follow-on investors.
Chuangjian Medical adheres to an independent innovation development path, has successively participated in national '13th Five-Year Plan' and '14th Five-Year Plan' key research and development projects as well as multiple provincial and municipal research topics. It has been rated as a high-tech enterprise and has received multiple honors including the national/provincial 'Little Giant' enterprise for specialized expertise and innovation, Jiangsu Postdoctoral Innovation Base, Jiangsu Engineering Technology Research Center, and potential unicorn enterprise in Jiangsu Province.
About Frost & Sullivan
Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') is a global growth consulting company. For over 63 years, Frost & Sullivan has been deeply involved in global capital markets and corporate consulting services through its nearly 50 offices around the world. Utilizing a powerful database and expert network, rich professional knowledge, and consulting tools, it has helped more than 10,000 clients (including Fortune Global 1000 companies, top domestic and international financial institutions, and various other leading enterprises) accelerate their business growth, helping them achieve growth, innovation, and leading benchmarks within their industries.
About Frost & Sullivan's Life Sciences Practice in Greater China
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and the cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life sciences industry. The Life Sciences Practice has a wide range of corporate clients in China and has established a vast client network over the past 20 years, accumulating extensive project experience across various sub-sectors of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities), Pre-IPO projects (DCF valuation, business plan services), IPO listing projects (industry consulting, clinical audit, fundraising and investment writing), market research, market value management, and strategic consulting, etc. In addition, we cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in professional niche fields such as pharmaceuticals and medical devices, attracting wide attention from investors.
